Anti-ITGB3 (Tadocizumab)-RGD-MMAE-HAS ADC (ADC-W-444)

This ADC product is comprised of an anti-ITGB3 monoclonal antibody conjugated via a RGD linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.

ADC Target

Name
ITGB3

Alternative Names
ITGB3; integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61); GT; CD61; GP3A; BDPLT2; GPIIIa; BDPLT16; integrin beta-3; platelet membrane glycoprotein IIIa;

Target Entrez Gene ID
3690

Target UniProt ID
P05106

Overview
The ITGB3 protein product is the integrin beta chain beta 3. Integrins are integral cell-surface proteins composed of an alpha chain and a beta chain. A given chain may combine with multiple partners resulting in different integrins. Integrin beta 3 is found along with the alpha IIb chain in platelets. Integrins are known to participate in cell adhesion as well as cell-surface mediated signalling.

ADC Antibody

Overview
Humanized Anti-ITGB3 Antibody, Tadocizumab

Generic name
Tadocizumab

Species Reactivity
Human

ADC Linker

Name
RGD

ADC payload drug

Name
MMAE (Monomethyl auristatin E)

Description
Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Related Products

Online Inquiry

Name:

*Phone:

*E-mail Address:

*Products or Services Interested:

Company/Institution

Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.

Contact us
USA

Tel:
Fax:
Email:
Europe

Tel:
Email:
Germany

Tel:
Email: